Celgene’s $34 Million Thalomid Antitrust Deal Approved by Judge

Celgene Corp. and the pension funds claiming it monopolized the market for two cancer drugs got the nod from a federal judge in New Jersey for a $34 million settlement of their antitrust dispute.

Judge Madeline Cox Arleo granted final approval to the agreement, which resolves proposed class action claims brought on behalf of insurers, pension funds, employers sponsoring health plans, and uninsured patients under the laws of about a dozen states.

Arleo also approved $11.3 million in fees and $3.6 million in expenses for class counsel—led by Hach Rose Schirripa & Cheverie LLP, Hausfeld LLP, and Block & Leviton ...